#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Congenital cystic kidney disease Short stature homeobox gene mutation Leukocyte adhesion deficiency Gastric cancer Deafness neurosensory Optic glioma Hepatic angiosarcoma Dementia Skin angiosarcoma Arteriosclerosis Sjogren's syndrome Retinitis pigmentosa Hypocalcaemia Alpha-1 antitrypsin deficiency B-cell small lymphocytic lymphoma recurrent More trials…

    Learn about Rare Diseases

    Wiskott-Aldrich syndrome – Life with Disease Hereditary ataxia Mucous membrane pemphigoid – Diagnostics Rhabdomyosarcoma – Life with Disease Angiosarcoma – Treatment Mantle cell lymphoma stage II – Diagnostics Ewing’s sarcoma – Treatment Leukoencephalopathy – Treatment Biotinidase deficiency – Life with Disease Alveolar rhabdomyosarcoma – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Itepekimab Levofloxacin Hemihydrate Histamine Dihydrochloride Fingolimod Doxorubicin Panobinostat Golexanolone Glpg3667 Fumarate AZD4360 Montelukast Abbv-668 Inclisiran Histidine Namodenoson SC0062 Doxorubicin Hydrochloride Efgartigimod Alfa Fadraciclib Wve-006 Carboplatin More therapies…

    Learn about Your Condition

    Dyspepsia Immune thrombocytopenia Post procedural infection Staphylococcal infection Metabolic disorder Thermal burn Chronic hepatic failure Haemorrhage intracranial Peripheral artery restenosis Neurodermatitis Actinic cheilitis Colonoscopy Viral infection Erythema multiforme Brain injury More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Universitetssykehuset Nord-Norge HF

Universitetssykehuset Nord-Norge HF

Hansine Hansens Veg 67, Tromsø, 9019, Norway

Want to learn more about this study or check if you can participate? Contact us.

  • Study Comparing Sirolimus and Methylprednisolone for Patients with Active Thyroid Eye Disease

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Sirolimus
    • Methylprednisolone
    Norway

  • Study on the Effectiveness of Abiraterone, Capivasertib, and Enzalutamide in Patients with Metastatic Prostate Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    • Prostate cancer metastatic
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Abiraterone
    • Anhydrous Docetaxel
    • Apalutamide
    Belgium Denmark Finland Norway Sweden

  • Study on the Long-term Safety of Guselkumab for Children with Crohn’s Disease, Ulcerative Colitis, or Juvenile Psoriatic Arthritis

    Recruiting

    3 1 1
    Investigated Drugs:
    • Guselkumab
    Belgium France Germany Italy Norway Poland +2

  • Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using Gemtuzumab Ozogamicin and a Drug Combination

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Daunorubicin Hydrochloride
    • Dexrazoxane
    • Etoposide Phosphate
    Belgium Denmark Estonia Finland Iceland Latvia +6

  • Study on Venetoclax and Drug Combination for Adults with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with Excess Blasts-2

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Daunorubicin
    • Cytarabine
    • Venetoclax
    Austria Belgium Estonia Finland Germany Lithuania +2

  • Study on the Safety and Effectiveness of Quizartinib for Children with Newly Diagnosed FLT3-ITD Positive AML and Normal NPM1

    Recruiting

    2 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Quizartinib Dihydrochloride
    Belgium Denmark Estonia Finland Iceland Latvia +6

  • Study on Apixaban for Preventing Stroke in Patients with Atrial Fibrillation and Stage 5 Chronic Kidney Disease

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Atrial fibrillation
    • Chronic kidney disease
    • End stage renal disease
    Investigated Drugs:
    • Apixaban
    Finland France Iceland The Netherlands Norway Poland +1

  • Study Comparing Trastuzumab Deruxtecan with Standard Treatment for Patients with HER2-positive Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Aprepitant
    • Betamethasone
    • Filgrastim
    Belgium The Netherlands Norway Sweden

  • Study on Atorvastatin for Preventing Chronic Migraine in Adults

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Migraine
    Investigated Drugs:
    • Atorvastatin
    • Placebo
    Norway

  • Study on Atorvastatin for Preventing Episodic Migraine in Adults

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Migraine
    Investigated Drugs:
    • Atorvastatin
    • Placebo
    Norway
Previous Page
1 … 4 5 6 7 8 … 13
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!